Treatment of Acute Antibody-Mediated Renal Allograft Rejection With Cyclophosphamide

被引:15
作者
Waiser, Johannes [1 ]
Duerr, Michael [1 ]
Budde, Klemens [1 ]
Rudolph, Birgit [2 ]
Wu, Kaiyin [1 ,2 ]
Bachmann, Friederike [1 ]
Halleck, Fabian [1 ]
Schonemann, Constanze [3 ]
Lachmann, Nils
机构
[1] Charite Univ Med Berlin, Med Klin Schwerpunkt Nephrol, Berlin, Germany
[2] Charite Univ Med Berlin, Inst Pathol, Berlin, Germany
[3] Charite, Zentrum Tumormed, HLA Labor, Berlin, Germany
关键词
DONOR-SPECIFIC ANTIBODIES; EULAR RECOMMENDATIONS; MANAGEMENT; RITUXIMAB; BORTEZOMIB;
D O I
10.1097/TP.0000000000001617
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Antibody-mediated rejection (AMR) is a major risk for renal allograft survival. Throughout decades, cyclophosphamide treatment has been proven to be effective in patients with antibody-associated autoimmune diseases. We investigated whether cyclophosphamide combined with plasmapheresis and intravenous immunoglobulins is an option for patients with AMR. Methods. Between March 2013 and November 2015, we initiated treatment of 13 consecutive patients with biopsy-proven acute AMR with intravenous cyclophosphamide pulses (15 mg/kg adapted to age and renal function) at 3-week intervals, PPH (6x), and high-dose intravenous immunoglobulin (1.5 g/kg). Treatment was completed after 6 cyclophosphamide pulses or in case of return to baseline serum creatinine together with reduction of donor-specific HLA antibodies (DSA) below 500 mean fluorescence intensity. Results. Eleven of 13 patients completed treatment. Median follow-up was 18 (12-44) months. At the end of follow-up, graft survival was 77%(10/13). The 3 graft losses were caused at least in part by nonadherence and premature termination of treatment. Serum creatinine increased from 1.7 +/- 0.4 mg/dL at 3 months before diagnosis to 3.7 +/- 2.4 mg/dL at diagnosis (P = 0.01), and decreased to 2.1 +/- 0.7 mg/dL at 3 months after diagnosis (P = 0.01). In 7 (64%) of 11 patients, who completed treatment, DSA decreased, in 4 (36%) of 11 DSA were below 500 mean fluorescence intensity after treatment. Dose reductions had to be performed in 3 of 13 patients for leukopenia. We observed 14 hospitalizations in 9 of 13 patients. Conclusions. To our knowledge, this is the first systematic report on cyclophosphamide-based treatment of acute AMR based on modern diagnostics. Treatment was effective and relatively safe. Future studies will show, whether cyclophosphamide proves to be a valuable alternative for the treatment of AMR.
引用
收藏
页码:2545 / 2552
页数:8
相关论文
共 32 条
  • [1] Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis
    Bertsias, George K.
    Tektonidou, Maria
    Amoura, Zahir
    Aringer, Martin
    Bajema, Ingeborg
    Berden, Jo H. M.
    Boletis, John
    Cervera, Ricard
    Doerner, Thomas
    Doria, Andrea
    Ferrario, Franco
    Floege, Juergen
    Houssiau, Frederic A.
    Ioannidis, John P. A.
    Isenberg, David A.
    Kallenberg, Cees G. M.
    Lightstone, Liz
    Marks, Stephen D.
    Martini, Alberto
    Moroni, Gabriela
    Neumann, Irmgard
    Praga, Manuel
    Schneider, Matthias
    Starra, Argyre
    Tesar, Vladimir
    Vasconcelos, Carlos
    van Vollenhoven, Ronald F.
    Zakharova, Helena
    Haubitz, Marion
    Gordon, Caroline
    Jayne, David
    Boumpas, Dimitrios T.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2012, 71 (11) : 1771 - 1782
  • [2] Bonomini V, 1985, Trans Am Soc Artif Intern Organs, V31, P698
  • [3] Treatment of antibody-mediated rejection in renal transplant patients: a clinical practice survey
    Burton, Stephanie A.
    Amir, Naaseha
    Asbury, Alaina
    Lange, Alex
    Hardinger, Karen L.
    [J]. CLINICAL TRANSPLANTATION, 2015, 29 (02) : 118 - 123
  • [4] Evidence-based management of ANCA vasculitis
    Carruthers, David
    Sherlock, Jonathan
    [J]. BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2009, 23 (03): : 367 - 378
  • [5] Pulse Versus Daily Oral Cyclophosphamide for Induction of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis A Randomized Trial
    de Groot, Kirsten
    Harper, Lorraine
    Jayne, David R. W.
    Suarez, Luis Felipe Flores
    Gregorini, Gina
    Gross, Wolfgang L.
    Luqmani, Rashid
    Pusey, Charles D.
    Rasmussen, Niels
    Sinico, Renato A.
    Tesar, Vladimir
    Vanhille, Philippe
    Westman, Kerstin
    Savage, Caroline O. S.
    [J]. ANNALS OF INTERNAL MEDICINE, 2009, 150 (10) : 670 - U3
  • [6] Review of Bortezomib Treatment of Antibody-Mediated Rejection in Renal Transplantation
    Ejaz, Nicole S.
    Alloway, Rita R.
    Halleck, Fabian
    Duerr, Michael
    Budde, Klemens
    Woodle, E. Steve
    [J]. ANTIOXIDANTS & REDOX SIGNALING, 2014, 21 (17) : 2401 - 2418
  • [7] Eskandary Farsad, 2014, Clin Transpl, P189
  • [8] Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trial
    Eskandary, Farsad
    Bond, Gregor
    Schwaiger, Elisabeth
    Kikic, Zeljko
    Winzer, Christine
    Wahrmann, Markus
    Marinova, Lena
    Haslacher, Helmuth
    Regele, Heinz
    Oberbauer, Rainer
    Boehmig, Georg A.
    [J]. TRIALS, 2014, 15
  • [9] RESISTANT HEPATIC ALLOGRAFT-REJECTION SUCCESSFULLY TREATED WITH CYCLOPHOSPHAMIDE AND PLASMAPHERESIS
    EVRARD, HM
    MILLER, C
    SCHWARTZ, M
    THUNG, SN
    MAYER, L
    [J]. TRANSPLANTATION, 1990, 50 (04) : 702 - 704
  • [10] Plasmapheresis and cyclophosphamide in the treatment of humoral rejection after heart transplantation
    Grauhan, O
    Knosalla, C
    Ewert, R
    Hummel, M
    Loebe, M
    Weng, YG
    Hetzer, R
    [J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2001, 20 (03) : 316 - 321